[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Nguyen et al., 2023 - Google Patents

H3G34-mutant gliomas—a review of molecular pathogenesis and therapeutic options

Nguyen et al., 2023

View HTML
Document ID
4053700221297386668
Author
Nguyen A
Soto J
Gonzalez S
Murillo J
Trumble E
Shan F
Huang J
Publication year
Publication venue
Biomedicines

External Links

Snippet

The 2021 World Health Organization Classification of Tumors of the Central Nervous System reflected advances in understanding of the roles of oncohistones in gliomagenesis with the introduction of the H3. 3-G34R/V mutant glioma to the already recognized H3-K27M altered …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/28—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for programming tools or database systems, e.g. ontologies, heterogeneous data integration, data warehousing or computing architectures
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
    • G06F19/18—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology for functional genomics or proteomics, e.g. genotype-phenotype associations, linkage disequilibrium, population genetics, binding site identification, mutagenesis, genotyping or genome annotation, protein-protein interactions or protein-nucleic acid interactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Similar Documents

Publication Publication Date Title
Olympios et al. TERT promoter alterations in glioblastoma: a systematic review
Kram et al. Embryonal tumors of the central nervous system in children: the era of targeted therapeutics
Kaminska et al. Single-cell omics in dissecting immune microenvironment of malignant gliomas—challenges and perspectives
Haase et al. Hemispherical pediatric high-grade glioma: Molecular basis and therapeutic opportunities
Masui et al. Molecular and genetic determinants of glioma cell invasion
Jungk et al. Location-dependent patient outcome and recurrence patterns in IDH1-wildtype glioblastoma
Nitika et al. Role of Biomarkers in FLT3 AML
Pappula et al. A genome-wide profiling of glioma patients with an IDH1 mutation using the catalogue of somatic mutations in cancer database
Vaidya et al. DNA associated with circulating exosomes as a biomarker for glioma
Voutsadakis Urothelial bladder carcinomas with high tumor mutation burden have a better prognosis and targetable molecular defects beyond immunotherapies
Shen et al. A novel classification model for lower-grade glioma patients based on pyroptosis-related genes
Da-Veiga et al. Glioma stem cells in pediatric high-grade gliomas: from current knowledge to future perspectives
Saccomani et al. miR-22-3p negatively affects tumor progression in T-cell acute lymphoblastic leukemia
Bruno et al. Glioblastoma in the elderly: Review of molecular and therapeutic aspects
Calvo Tardón et al. An experimentally defined hypoxia gene signature in glioblastoma and its modulation by metformin
Giotta Lucifero et al. Immune landscape in PTEN-related glioma microenvironment: A bioinformatic analysis
Idilli et al. Changes in the expression of pre-replicative complex genes in hTERT and ALT pediatric brain tumors
Lopez-Nunez et al. Melanotic neuroectodermal tumor of infancy (MNTI) and pineal anlage tumor (PAT) harbor a medulloblastoma signature by DNA methylation profiling
Montesinos-Rongen et al. Impact of a faulty germinal center reaction on the pathogenesis of primary diffuse large B cell lymphoma of the central nervous system
Pisanu et al. Genetic and epigenetic markers of lithium response
Agosti et al. Tumor microenvironment and glioblastoma cell interplay as promoters of therapeutic resistance
Chen et al. Clinical significance and systematic expression analysis of the thyroid receptor interacting protein 13 (TRIP13) as human gliomas biomarker
Nguyen et al. H3G34-mutant gliomas—a review of molecular pathogenesis and therapeutic options
Liang et al. Abemaciclib, a selective CDK4/6 inhibitor, restricts the growth of pediatric ependymomas
Shi et al. TNFR1 and TNFR2, which link NF-κB activation, drive lung cancer progression, cell dedifferentiation, and metastasis